Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Overview of attention for article published in Journal of Clinical Oncology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 42 news outlets
blogs: 3 blogs

twitter: 46 X users
facebook: 2 Facebook pages

Citations

dimensions_citation: 98 Dimensions

Readers on

mendeley: 85 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 3 posts from 3 blogs.

Ús del palbociclib adjuvant per a càncer de pit primerenc

Infosalut, 14 Feb 2022

El Servei d'Oncologia de l'Hospital Universitari Son Espases ha participat en la publicació de l'assaig PALLAS sobre l'ús del…

Two years of adjuvant Palbociclib added to endocrine therapy does not improve outcomes in early breast cancer

Grey Horizon, 13 Dec 2021

Results of a phase III trial, the Palbociclib CoLlaborative Adjuvant Study (PALLAS), presented at the 2021 San Antonio Breast…

PALLAS: Add-On CDK4/6 Inhibitor for Breast Ca Disappoints

Physician's Weekly, 09 Dec 2021

When added to endocrine Rx, palbociclib did not best endocrine therapy…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.